EP251: mRNA and Amyloid

Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I’m a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients. Podcast Episode Summary Introduction Dr. Warrick Bishop, a cardiologist, author, and CEO of the Healthy Heart Network, hosts this episode focused on emerging medical technologies discussed at the 2022 Cardiac Society conference. The episode explores two groundbreaking areas—mRNA applications and amyloid accumulation—and their significant implications for preventing heart disease and improving global health outcomes. Key Takeaways: mRNA serves as a transcription factor that carries genetic blueprints from DNA to cells, enabling the production of specific proteins and offering vast therapeutic potential beyond COVID vaccines. mRNA technology allows doctors to insert information into cells to trigger immune responses, demonstrated effectively by Pfizer and Moderna COVID vaccines using spike protein sequences. Small interfering RNA particles can block the production of harmful proteins like PCSK9 in the liver, potentially replacing current antibody-based cholesterol treatments with more efficient prevention methods. Over 50 Nobel Prizes in Medicine have been awarded for mRNA research, with more than 2,500 mRNA proteins identified, representing an enormous body of scientific work and future medical opportunities. Elevated mRNA proteins can serve as biomarkers to detect cellular stress and strain, particularly in cardiac failure, allowing for earlier diagnosis and intervention. Amyloid is a protein that accumulates in organs like the heart and brain instead of being cleared, contributing to heart stiffness and potentially Alzheimer's disease. Amyloid accumulation can result from plasma cell tumors (myeloma), age-related factors, or genetic predisposition from liver production, making it a complex but increasingly manageable condition. mRNA-based therapies show promise for targeting and blocking amyloid protein production, representing a convergence of these two emerging medical technologies for better treatment outcomes.